The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice

The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice

Oxaliplatin, the first-line chemotherapeutic agent against colorectal cancer (CRC), induces peripheral neuropathies, which can lead to dose limitation and treatment discontinuation. Downregulation of potassium channels, which involves histone deacetylase (HDAC) activity, has been identified as an im...

Full description

Bibliographic Details
Main Authors: Sylvain Lamoine, Mélissa Cumenal, David A. Barriere, Vanessa Pereira, Mathilde Fereyrolles, Laëtitia Prival, Julie Barbier, Ludivine Boudieu, Emilie Brasset, Benjamin Bertin, Yoan Renaud, Elisabeth Miot-Noirault, Marie-Ange Civiale, David Balayssac, Youssef Aissouni, Alain Eschalier, Jérôme Busserolles
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:International Journal of Molecular Sciences
Subjects:
colorectal cancer
oxaliplatin
peripheral neuropathy
histone deacetylase inhibitor
MS-275
<i>APC<sup>Min/+</sup></i> mice
Online Access:https://www.mdpi.com/1422-0067/23/1/98

Internet

https://www.mdpi.com/1422-0067/23/1/98

Similar Items